Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
By Chaolin Huang, Ye-ming Wang, Xingwang Li, L. Ren, Jianping Zhao, Yi Hu, Li Zhang, Guohui Fan, Jiuyang Xu, Xiaoying Gu and 19 more. The Lancet, 2020
12,051 citations recorded by the source corpus.
Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.
Subfields: Immunology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/7724b78d3d9275bc93d8c651d74ab6c5fc459736
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Aviv Regev
- G. Dimopoulos
- T. Hirano
- Mihai G. Netea
- A. Misharin
- Zemin Zhang
- Joachim L. Schultze
- Ivan Dikic
In Infectious Diseases
- Ralph S. Baric
- Annelies Wilder-Smith
- G. Dimopoulos
- T. Hirano
- Mihai G. Netea
- Ysrafil
- Yizhao Peng
- Xiaowei Li
Citations in the corpus
- Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis (2020, background): “For confirmed COVID-19 cases, reported the common clinical symptoms include fever, cough, myalgia or fatigue.(8) Yet these symptoms are not unique features of COVID-19 because these symptoms are similar to that of other virusinfected disease such as influenza.”
- Coronavirus disease 2019 (COVID-19) pandemic and pregnancy (2020, neutral): “Patients with SARS showed preferential activation of Th1 immunity, resulting in themarked elevation of proinflammatory cytokines (IFNg, IL-1b, IL-6, and IL-12) for at least 2 weeks after disease onset, leading to extensive lung damage.13 In contrast, patients with COVID-19 demonstrated activation of”
- ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection (2020, neutral): “The disease primarily involves the respiratory tract [1e5] but it may deteriorate to multi-organ failure and be fatal [3].”
- Clinical Characteristics of Coronavirus Disease 2019 in China (2020, neutral): “org I n early December 2019, the first pneumonia cases of unknown origin were identified in Wuhan, the capital city of Hubei province.(1) The pathogen has been identified as a novel enveloped RNA betacoronavirus(2) that has currently been named severe acute respiratory syndrome coronavirus 2 (SARS-C”
- A Review of Coronavirus Disease-2019 (COVID-19) (2020, positive): “Studies have shown that, patients suffering from severe pneumonia, with common symptoms of fever and dry cough at onset of illness [7,8].”
- The Role of Imaging in the Detection and Management of COVID-19: A Review (2020, background): “Follow-up CT checking images reveal temporal changes in imaging characteristics for COVID-19 [18], [22], [23], [32], [61]–[65].”
- Effectiveness of convalescent plasma therapy in severe COVID-19 patients (2020, neutral): “significantly higher than in those who did not require ICU conditions (2, 18).”
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 (2020, neutral): “, 2020), and many patients with COVID-19 present with cardiovascular and renal dysfunctions (Huang et al., 2020; Yang et al., 2020; Zhang et al., 2020a; Zhou et al., 2020a).”
- A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 (2020, neutral): “The results of these trials will be the fi rst available on humans, since studies published to date on the characteristics and management of patients with COVID-19 did not report dataabout chloroquineuse[1,12 – 15].”